Neurodegeneration in Alzheimer disease (AD) is thought to be driven by a complex interaction of multiple molecular and physiologic brain changes that take place over decades before the onset of… Click to show full abstract
Neurodegeneration in Alzheimer disease (AD) is thought to be driven by a complex interaction of multiple molecular and physiologic brain changes that take place over decades before the onset of clinical symptoms. Understanding how early brain changes may instigate neurodegeneration in preclinical AD, which is defined by the presence of amyloid plaques in the absence of cognitive symptoms,1 is important for the development of therapies to prevent or delay cognitive impairment.
               
Click one of the above tabs to view related content.